Yosuke Omori1, Toshiaki Mano2, Tomohito Ohtani1, Yasushi Sakata1, Yasuharu Takeda1, Shunsuke Tamaki1, Yasumasa Tsukamoto1, Takeshi Miwa3, Kazuhiro Yamamoto4, Issei Komuro5. 1. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. 2. †Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan. 3. ‡Genome Information Research Center, Osaka University, Suita 565-0871, Japan. 4. §Division of Molecular Medicine and Therapeutics, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, Japan. 5. ¶Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku 113-0033, Japan.
Abstract
BACKGROUND: Cardiac fibrosis is considered to be a crucial factor in the development of heart failure. Blockade of the mineralocorticoid receptor (MR) attenuated cardiac fibrosis and improved the prognosis of patients with chronic heart failure but the ligand for MR and the regulatory mechanism of MR pathway in the diseased heart are unclear. Here, we investigated whether glucocorticoids can promote cardiac fibrosis through MR in oxidative stress and the involvement of elongation factor eleven-nineteen lysine-rich leukemia (ELL), a co-activator of MR, in this pathway. METHODS AND RESULTS: The MR antagonist eplerenone attenuated corticosterone-induced collagen synthesis assessed by [(3)H]proline incorporation in rat neonatal cultured cardiac fibroblasts in the presence of H2O2, as an oxidative stress but not in the absence of H2O2. H2O2 increased the ELL expression levels and MR-bound ELL. ELL expression levels and MR-bound ELL were also increased in the left ventricle of heart failure model rats with significant fibrosis and enhanced oxidative stress. Eplerenone did not attenuate corticosterone-induced increase of [(3)H]proline incorporation in the presence of H2O2 after knockdown of ELL expression using small interfering RNA in cardiac fibroblasts. CONCLUSION: Glucocorticoids can promote cardiac fibrosis via MR in oxidative stress, and oxidative stress modulates MR response to glucocorticoids through the interaction with ELL. Preventing cardiac fibrosis by modulating glucocorticoid-MR-ELL pathway may become a new therapeutic strategy for heart failure.
BACKGROUND:Cardiac fibrosis is considered to be a crucial factor in the development of heart failure. Blockade of the mineralocorticoid receptor (MR) attenuated cardiac fibrosis and improved the prognosis of patients with chronic heart failure but the ligand for MR and the regulatory mechanism of MR pathway in the diseased heart are unclear. Here, we investigated whether glucocorticoids can promote cardiac fibrosis through MR in oxidative stress and the involvement of elongation factor eleven-nineteen lysine-rich leukemia (ELL), a co-activator of MR, in this pathway. METHODS AND RESULTS: The MR antagonist eplerenone attenuated corticosterone-induced collagen synthesis assessed by [(3)H]proline incorporation in rat neonatal cultured cardiac fibroblasts in the presence of H2O2, as an oxidative stress but not in the absence of H2O2. H2O2 increased the ELL expression levels and MR-bound ELL. ELL expression levels and MR-bound ELL were also increased in the left ventricle of heart failure model rats with significant fibrosis and enhanced oxidative stress. Eplerenone did not attenuate corticosterone-induced increase of [(3)H]proline incorporation in the presence of H2O2 after knockdown of ELL expression using small interfering RNA in cardiac fibroblasts. CONCLUSION: Glucocorticoids can promote cardiac fibrosis via MR in oxidative stress, and oxidative stress modulates MR response to glucocorticoids through the interaction with ELL. Preventing cardiac fibrosis by modulating glucocorticoid-MR-ELL pathway may become a new therapeutic strategy for heart failure.
Authors: Gülmisal Güder; Johann Bauersachs; Stefan Frantz; Dirk Weismann; Bruno Allolio; Georg Ertl; Christiane E Angermann; Stefan Störk Journal: Circulation Date: 2007-03-19 Impact factor: 29.690
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: O C Meijer; E Kalkhoven; S van der Laan; P J Steenbergen; S H Houtman; T F Dijkmans; D Pearce; E R de Kloet Journal: Endocrinology Date: 2004-11-24 Impact factor: 4.736
Authors: T Masuyama; K Yamamoto; Y Sakata; R Doi; N Nishikawa; H Kondo; K Ono; T Kuzuya; M Sugawara; M Hori Journal: J Am Coll Cardiol Date: 2000-12 Impact factor: 24.094
Authors: Margarita Pizarro; Nancy Solís; Pablo Quintero; Francisco Barrera; Daniel Cabrera; Pamela Rojas-de Santiago; Juan P Arab; Oslando Padilla; Juan C Roa; Han Moshage; Alexander Wree; Eugenia Inzaugarat; Ariel E Feldstein; Carlos E Fardella; Rene Baudrand; Arnoldo Riquelme; Marco Arrese Journal: Liver Int Date: 2015-02-23 Impact factor: 5.828
Authors: Navya M Reddy; Umesh B Mahajan; Chandragouda R Patil; Yogeeta O Agrawal; Shreesh Ojha; Sameer N Goyal Journal: Am J Transl Res Date: 2015-09-15 Impact factor: 4.060